IMAB News and Press, I-MAB From 06/22/23

I-Mab Announces the Appointment of Raj Kannan as CEO PR Newswire GAITHERSBURG, Md. and SHANGHAI , June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, developme...

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 PR Newswire - Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activa...

I-MAB Filed 2022 Annual Report on Form 20-F PR Newswire GAITHERSBURG, Md. and SHANGHAI , May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and comme...

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 PR Newswire GAITHERSBURG, Md. and SHANGHAI , April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to...

2023-04-25 06:01:16 ET I-Mab ( NASDAQ: IMAB ) said an arbitration tribunal awarded no damages to Tracon Pharmaceuticals ( NASDAQ: TCON ) related to a collaboration agreement but the company would have to pay part of Tracon's legal fees of ~$13.5M. Chinese biote...

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon PR Newswire Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's groundless damages c...

2023-04-24 09:36:47 ET Summary Today, we take our first look at I-Mab which has three late stage drug candidates in development. The company has a significant potential collaboration deal with AbbVie and the stock trades significantly below net discount. Is this large 'Chinese...

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China PR Newswire GAITHERSBURG, Md. and SHANGHAI , April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharm...

2023-03-31 11:52:03 ET I-Mab (IMAB) Q4 2022 Earnings Conference Call March 31, 2023, 8:15 AM ET Company Participants Tyler Ehler - Senior Director of Investor Relations Andrew Zhu - Acting Chief Executive Officer Richard Yeh - Interim Chief Financial Officer and ...

2023-03-31 06:43:48 ET I-Mab Biopharma press release ( NASDAQ: IMAB ): FY Non-GAAP EPADS of -$3.58 misses by $2.75 . Revenue of $32.1M (vs.$13.8M Y/Y) misses by $69.23M . A strong cash position of  $514.2M by the end of 2022, sufficient to fund key bu...